New data presented from large studies consolidating the effectiveness, safety and tolerability of Sativex in patients with spasticity symptoms in MS

Almirall, the global pharmaceutical company based in Barcelona, presented new clinical evidences of Sativex®, the only medicine derived from cannabinoids to treat spasticity symptoms in MS, within the context of the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Barcelona from 7 to 10th of October. In the context of this congress, experts have discussed the different aspects of the disease, including spasticity impact on patients quality of life and the specifics of its treatment with Sativex®.

MS affects…

Favicon of da :

Prosegui la lettura...
Traduci l'articolo...

Sclerosi Multipla News

Potrebbe interessarti anche

Argomenti correlati